CannaPharmaRX, Inc.

CPMD

US13765D1090

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 08:41:06 28/06/2024 pm IST			5-day change	1st Jan Change
0.014 ^USD	+27.27%		+12.00%	+723.53%

25/06	CannaPharmaRX, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04/06	CannaPharmaRX, Inc. Executes Multi-Year Supply Agreement with ICAN Green S.A. de C.V to Create Distribution Network in the Latin Americas	CI

CannaPharmaRX, Inc. Announces Resignation of Wendy Dicicco as Director

June 02, 2016 at 03:34 pm IST

On January 11, 2016, Wendy DiCicco resigned as a Director of CannaPharmaRX, Inc. Her resignation was accepted at the time by then-Interim President Jim Smeeding.

Latest news about CannaPharmaRX, Inc.

CannaPharmaRX, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	26/06	CI
CannaPharmaRX, Inc. Executes Multi-Year Supply Agreement with ICAN Green S.A. de C.V to Create Distribution Network in the Latin Americas	05/06	CI
CannaPharmaRX, Inc. Receives First Purchase Order	05/06	CI
CannaPharmaRX, Inc. Announces CEO Changes	05/06	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	17/05	CI
CannaPharmaRX, Inc. Receives First Purchase Order and Begins Shipment of Product	14/03	CI
CannaPharmaRX, Inc. Executes Multi-Year Supply Agreement with Ican to Create Distribution Network in the Latin Americas	05/03	CI
CannaPharmaRx, Inc Enters into Strategic Supply Agreement with Cantek Holdings	17/02	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	18/11	CI
CannaPharmaRX, Inc. Announces Executive Changes	14/23/14	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	13/23/13	CI
CannaPharmaRX, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23/23/23	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
CannaPharmaRx Expands Board of Directors	25/23/25	CI
CannaPharmaRX, Inc. Announces CEO Changes	23/23/23	CI
CannaPharmaRX, Inc. Signs Supply Agreement with Y.S.A Holdings for Up to $15 Million Annually of Commercial Cannabis	30/23/30	CI
CannaPharmaRX, Inc. completed the acquisition of LTB Management LLC.	21/23/21	CI
CannaPharmaRX, Inc. agreed to acquire LTB Management LLC.	21/23/21	CI
CannaPharmaRx Receives Canada Revenue Agency License As Final Step to Bringing Facility Into Production With Annual Revenues of Over $30 Million Expected	11/23/11	CI
CannaPharmaRx, Inc Receives Cultivation License from Health Canada and Projects 2023 Revenue over $30 Million	21/22/21	CI
CannaPharmaRX, Inc. Provides Revenue Guidance for the Full Year 2023	21/22/21	CI
CannaPharmaRx, Inc. Receives Cultivation License from Health Canada	21/22/21	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22/22/22	CI
CannaPharmaRX, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	23/22/23	CI
CannaPharmaRX, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	23/22/23	CI

CannaPharmaRx, Inc. is focused on the acquisition and development of state-of-the-art cannabis growing facilities in Canada. The Company is engaged in producing customizable medical cannabis and craft products. Its business strategy is to produce a high quality and low-cost production of cannabis through the development, acquisition, and enhancement of existing facilities. The Company is focused on operating high-quality facilities utilizing the latest technology in combined heat and power generation to ensure being a low-cost producer of cannabis. The Company also offers a range of services to assist with cannabis inventory management.

Sector

Pharmaceuticals

Calendar

19/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CANNAPHARMARX, INC.	+723.53%	9.19M
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+44.05%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B

Other Pharmaceuticals